Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Sarepta management to meet virtually with Piper Sandler » 08:29
07/10/20
07/10
08:29
07/10/20
08:29
SRPT

Sarepta

$170.35 /

+0.4 (+0.24%)

Virtual Meetings with…

Virtual Meetings with Management July 13-14 hosted by Piper Sandler.

ShowHide Related Items >><<
SRPT Sarepta
$170.35 /

+0.4 (+0.24%)

SRPT Sarepta
$170.35 /

+0.4 (+0.24%)

07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
SRPT Sarepta
$170.35 /

+0.4 (+0.24%)

SRPT Sarepta
$170.35 /

+0.4 (+0.24%)

SRPT Sarepta
$170.35 /

+0.4 (+0.24%)

Over a week ago
Recommendations
Sarepta's recent deals may expand eligible patient set, says William Blair » 11:50
07/02/20
07/02
11:50
07/02/20
11:50
SRPT

Sarepta

$164.00 /

-1.585 (-0.96%)

, HNSBF

Hansa Biopharma

$0.00 /

+ (+0.00%)

William Blair analyst Tim…

William Blair analyst Tim Lugo noted that Sarepta Therapeutics (SRPT) announced an agreement with Hansa Biopharma (HNSBF) for a worldwide license to develop and promote the latter's imlifidase as a pre-treatment to enable gene therapy administration in DMD and LGMD for patients who otherwise may not be eligible for treatment due to preexisting immunity. Hansa's technology may expand the number of patients who could benefit from treatment with Sarepta's gene therapy assets, said Lugo, who noted that this is the company's third deal in as many weeks for a technology that may help overcome issues with preexisting immunity and enable treatment of a broader set of patients. Lugo has an Outperform rating on Sarepta shares.

ShowHide Related Items >><<
SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
HNSBF Hansa Biopharma
$0.00 /

+ (+0.00%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

Hot Stocks
Sarepta signs agreement with Hansa Biopharma for imlifidase » 07:02
07/02/20
07/02
07:02
07/02/20
07:02
SRPT

Sarepta

$165.59 /

+5.275 (+3.29%)

Sarepta Therapeutics…

Sarepta Therapeutics announced an agreement with Hansa Biopharma for imlifidase. Under the terms of the agreement, Sarepta obtains an exclusive, worldwide license to develop and promote imlifidase as a pre-treatment to enable Sarepta gene therapy administration in Duchenne muscular dystrophy and Limb-girdle muscular dystrophy, for patients who may otherwise not be eligible for treatment. Sarepta's investigational gene therapies use an adeno-associated virus and patients with Duchenne and LGMD who have pre-existing IgG antibodies are not currently eligible for treatment with any AAV-based gene therapies. Imlifidase is an antibody-cleaving enzyme that specifically targets IgG and inhibits an IgG-mediated immune response. Imlifidase has a rapid onset of action, cleaving IgG-antibodies and inhibiting their reactivity within hours after administration, thus clearing the AAV-IgG antibodies that would typically preclude dosing or re-dosing with AAV. Under the terms of the agreement, Hansa will receive an upfront payment of $10M and is eligible for additional development, regulatory and sales milestone payments potentially totaling up to $397.5M. Hansa will book all sales of imlifidase and will earn tiered royalties up to the mid-teens on any incremental gene therapy sales that arise from treating antibody-positive patients enabled through imlifidase pre-treatment.

ShowHide Related Items >><<
SRPT Sarepta
$165.59 /

+5.275 (+3.29%)

SRPT Sarepta
$165.59 /

+5.275 (+3.29%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
SRPT Sarepta
$165.59 /

+5.275 (+3.29%)

SRPT Sarepta
$165.59 /

+5.275 (+3.29%)

SRPT Sarepta
$165.59 /

+5.275 (+3.29%)

Hot Stocks
Sarepta CFO, CBO Sandy Mahatme to retire » 08:31
06/30/20
06/30
08:31
06/30/20
08:31
SRPT

Sarepta

$162.63 /

-0.23 (-0.14%)

Sarepta Therapeutics…

Sarepta Therapeutics announced the retirement of Sandy Mahatme, Sarepta's EVP, CFO and chief business officer, from the company effective July 10, 2020. The company has commenced a search process to identify the future chief financial officer. During the interim period, the finance and accounting functions will report directly to Sarepta's CEO, Doug Ingram, and other departments reporting to Mr. Mahatme will be overseen by members of Sarepta's executive committee.

ShowHide Related Items >><<
SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

Conference/Events
Sarepta management to meet virtually with Mizuho » 04:55
06/30/20
06/30
04:55
06/30/20
04:55
SRPT

Sarepta

$162.63 /

-0.23 (-0.14%)

Virtual Meeting to be…

Virtual Meeting to be held on June 30 hosted by Mizuho.

ShowHide Related Items >><<
SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

SRPT Sarepta
$162.63 /

-0.23 (-0.14%)

Hot Stocks
Sarepta completes submission of NDA for casimersen in DMD » 08:31
06/26/20
06/26
08:31
06/26/20
08:31
SRPT

Sarepta

$167.23 /

+4.01 (+2.46%)

Sarepta Therapeutics…

Sarepta Therapeutics announced the Company has completed the submission of a rolling New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for casimersen. Casimersen, a phosphorodiamidate morpholino oligomer, is engineered to treat patients with Duchenne muscular dystrophy who have genetic mutations that are amenable to skipping exon 45 of the Duchenne gene. The completion of the rolling submission includes data from the casimersen arm of the ESSENCE study, a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating efficacy and safety in patients amenable to skipping exons 45 and 53. An interim analysis from ESSENCE demonstrated a statistically significant increase in dystrophin production as measured by western blot in patients who received casimersen compared to baseline and placebo. The study is ongoing, and remains blinded to collect additional efficacy and safety data. If the casimersen NDA is accepted and granted accelerated approval, the completed ESSENCE study will serve as a post-marketing confirmatory study.

ShowHide Related Items >><<
SRPT Sarepta
$167.23 /

+4.01 (+2.46%)

SRPT Sarepta
$167.23 /

+4.01 (+2.46%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
SRPT Sarepta
$167.23 /

+4.01 (+2.46%)

SRPT Sarepta
$167.23 /

+4.01 (+2.46%)

SRPT Sarepta
$167.23 /

+4.01 (+2.46%)

Conference/Events
Sarepta management to meet virtually with Mizuho » 08:43
06/25/20
06/25
08:43
06/25/20
08:43
SRPT

Sarepta

$163.22 /

-5.64 (-3.34%)

Virtual Meeting to be…

Virtual Meeting to be held on June 30 hosted by Mizuho.

ShowHide Related Items >><<
SRPT Sarepta
$163.22 /

-5.64 (-3.34%)

SRPT Sarepta
$163.22 /

-5.64 (-3.34%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
SRPT Sarepta
$163.22 /

-5.64 (-3.34%)

SRPT Sarepta
$163.22 /

-5.64 (-3.34%)

SRPT Sarepta
$163.22 /

-5.64 (-3.34%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/24/20
06/24
04:55
06/24/20
04:55
ALXN

Alexion

$115.44 /

-1.47 (-1.26%)

, JNJ

Johnson & Johnson

$142.86 /

-0.52 (-0.36%)

, NBIX

Neurocrine

$127.61 /

+0.17 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$168.86 /

-3 (-1.75%)

, ALNY

Alnylam

$152.00 /

-0.91 (-0.60%)

, BTAI

BioXcel Therapeutics

$58.53 /

+1.57 (+2.76%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
SRPT Sarepta
$168.86 /

-3 (-1.75%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

ALNY Alnylam
$152.00 /

-0.91 (-0.60%)

SRPT Sarepta
$168.86 /

-3 (-1.75%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.61 /

+0.17 (+0.13%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

JNJ Johnson & Johnson
$142.86 /

-0.52 (-0.36%)

BTAI BioXcel Therapeutics
$58.53 /

+1.57 (+2.76%)

ALXN Alexion
$115.44 /

-1.47 (-1.26%)

Conference/Events
BofA to hold a virtual conference » 04:55
06/23/20
06/23
04:55
06/23/20
04:55
ALXN

Alexion

$116.91 /

-2.36 (-1.98%)

, JNJ

Johnson & Johnson

$143.38 /

-0.63 (-0.44%)

, NBIX

Neurocrine

$127.44 /

-0.65 (-0.51%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SRPT

Sarepta

$171.86 /

+3.36 (+1.99%)

, ALNY

Alnylam

$152.91 /

+3.23 (+2.16%)

, BTAI

BioXcel Therapeutics

$56.96 /

+4.27 (+8.10%)

Napa Healthcare Virtual…

Napa Healthcare Virtual Conference will be held on June 22-24.

ShowHide Related Items >><<
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

06/12/20 Piper Sandler
Piper says competitive updates present 'very little' potential impact on Alexion
06/01/20 Wedbush
Alexion price target raised to $138 from $120 at Wedbush
06/01/20 Credit Suisse
Alexion price target raised to $147 from $142 at Credit Suisse
05/28/20 Raymond James
Raymond James keeps Outperform on Alexion after IP settlement analysis
JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

05/29/20 H.C. Wainwright
H.C. Wainwright sees path forward for Minerva's roluperidone despite setback
05/12/20 Oppenheimer
Novavax price target raised to $38.50 from $19 at Oppenheimer
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/29/20 Barclays
Johnson & Johnson price target raised to $182 from $173 at Barclays
NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

06/18/20 JPMorgan
Neurocrine price target raised to $134 from $122 at JPMorgan
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
06/17/20 H.C. Wainwright
Neurocrine price target raised to $131 from $125 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

06/10/20 SunTrust
Arcus Biosciences price target raised to $45 from $22 at SunTrust
06/10/20 Morgan Stanley
Morgan Stanley calls Merck bladder cancer failure 'marginal perception negative'
05/15/20 Barclays
Roche price target raised to CHF 395 from CHF 385 at Barclays
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

06/05/20 Guggenheim
Guggenheim starts BioXcel Therapeutics at Buy on optimistic view of lead asset
06/04/20 Guggenheim
BioXcel Therapeutics initiated with a Buy at Guggenheim
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
BioXcel Therapeutics initiated with a Buy at BofA
SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

ALNY Alnylam
$152.91 /

+3.23 (+2.16%)

SRPT Sarepta
$171.86 /

+3.36 (+1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NBIX Neurocrine
$127.44 /

-0.65 (-0.51%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

JNJ Johnson & Johnson
$143.38 /

-0.63 (-0.44%)

BTAI BioXcel Therapeutics
$56.96 /

+4.27 (+8.10%)

ALXN Alexion
$116.91 /

-2.36 (-1.98%)

Conference/Events
Sarepta participates in a conference call with JPMorgan » 09:37
06/22/20
06/22
09:37
06/22/20
09:37
SRPT

Sarepta

$168.50 /

+3.27 (+1.98%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Rama holds a conference call with CEO Ingram on June 22 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

SRPT Sarepta
$168.50 /

+3.27 (+1.98%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.